Probuphine Panel Review Could Be A Test Of Titan’s Delivery Technology
This article was originally published in The Pink Sheet Daily
FDA will convene an advisory committee review of the buprenorphine implant for opioid dependence – an established use for the drug, but the first in an extended-release delivery system.
You may also be interested in...
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.